Analysts See $-0.46 EPS for ObsEva SA (OBSV); Farmmi – Ordinary Shares (FAMI) Shorts Up By 41.67%

April 17, 2018 - By Hazel Jackson

Analysts expect ObsEva SA (NASDAQ:OBSV) to report $-0.46 EPS on May, 17.They anticipate $0.12 EPS change or 20.69% from last quarter’s $-0.58 EPS. After having $-0.48 EPS previously, ObsEva SA’s analysts see -4.17% EPS growth. The stock increased 2.00% or $0.26 during the last trading session, reaching $13.28. About 3,130 shares traded. ObsEva SA (NASDAQ:OBSV) has risen 20.97% since April 17, 2017 and is uptrending. It has outperformed by 9.42% the S&P500.

Farmmi Inc – Ordinary Shares (NASDAQ:FAMI) had an increase of 41.67% in short interest. FAMI’s SI was 1,700 shares in April as released by FINRA. Its up 41.67% from 1,200 shares previously. The stock decreased 0.38% or $0.03 during the last trading session, reaching $7.89. About 111,834 shares traded. Farmmi, Inc. (NASDAQ:FAMI) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Farmmi, Inc. processes and sells agricultural products in China, the United States, Japan, Canada, Europe, and the Middle East. The company has market cap of $91.93 million. The firm offers shiitake and Mu Er mushrooms; and other edible fungi products, including bamboo fungi, agrocybe aegerila, pleurotus eryngii, grifola frondosa, coprinus comatus, and hericium erinaceus. It has a 24.13 P/E ratio. It also trades in other agricultural products, such as tea.

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. The company has market cap of $493.10 million. The firm intends to develop products for treating endometriosis, uterine fibroids, and preterm labor, as well as for enhancing clinical pregnancy and live birth rates in women undergoing IVF. It currently has negative earnings. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF; and OBE022, an oral and selective prostaglandin F2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of pregnancy.

ObsEva SA (NASDAQ:OBSV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: